Novo Nordisk (NVO) said Friday the US Food and Drug Administration accepted its new drug application filing for an investigational 25 mg oral formulation of its obesity management drug Wegovy.
The FDA application for the oral Glucagon-like peptide-1 treatment is based on the results of a phase 3 trial, according to a statement.
The FDA will make a final decision on the application in Q4, the company said.
Wegovy injection 2.4 mg is currently approved for adults and children aged 12 years and older with obesity.
Shares were up 5.6% in recent trading.
Price: 69.18, Change: +3.58, Percent Change: +5.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。